my personal edition > cholesterol/lipid disorders > news


  E-Mail this DGNews to a colleague

DGNews

FDA Advisory Committee Unanimously Recommends Approval of Lipid Lowering Drug, Crestor (Rosuvastatin Calcium)

WILMINGTON, DE -- July 10, 2003 -- AstraZeneca Pharmaceuticals (NYSE: AZN) announced that the Endocrinologic and Metabolic Advisory Committee to the U.S. Food and Drug Administration (FDA) voted unanimously to recommend approval for CrestorŽ (rosuvastatin calcium) as an adjunct to diet for the treatment of various lipid disorders including hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. The FDA will now review the Committee's recommendation and make its final decision on granting marketing approval for Crestor.

"The Committee's unanimous recommendation to approve Crestor represents a vote of confidence in the clinical profile of Crestor," said Howard Hutchinson, Vice President of Clinical Research, AstraZeneca. "We believe that once approved, Crestor will provide patients who are untreated or not at their target cholesterol levels with an important new treatment option in the control of elevated cholesterol."

The clinical development program for Crestor is the largest pre-approval program ever submitted to evaluate the safety and efficacy of a new statin. More than 12,500 patients are included in the safety database with more than 4,000 patients exposed to the 40 mg dose. The most commonly reported treatment-related adverse events were myalgia, abdominal pain, nausea and asthenia.

Crestor belongs to the class of lipid-lowering medications called HMG- CoA reductase inhibitors, or "statins" and has been studied in more than 24,000 patients worldwide. Crestor is being studied in an extensive clinical outcomes program known as GALAXY, which includes more than 19,000 patients from 23 countries.

AstraZeneca licensed worldwide rights to Crestor from the Japanese pharmaceutical company Shionogi & Co., Ltd. Crestor was first approved in the Netherlands in 2002 and approval has recently been granted in 23 other countries. Launches have occurred in a number of countries, including Canada, the Netherlands and the United Kingdom.


SOURCE: AstraZeneca

E-Mail this DGNews to a colleague

To print, use this version